Adicet Bio

Adicet Bio Receivables

Accounts Receivable of Adicet Bio (ACET) as of Oct 30, 2026.

Receivables

0.00USD

Last updated:

Accounts Receivable of Adicet Bio is 2022 0.00 USD. Accounts Receivable of Adicet Bio was 2021 200,000.00 USD. It decreases by % lower compared to the previous year.

The Adicet Bio Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2021
200,000.00 USD
Jan 1, 2022
0.00 USD
The Adicet Bio Receivables history
YEARReceivablesYoY
0.00USD-100.00%
200,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Adicet Bio Stock analysis

What does Adicet Bio do? Adicet Bio, Inc. develops off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases, focusing on engineered gamma delta T cells with chimeric antigen receptors and T cell receptor-like antibodies. The company's pipeline includes ADI-001 targeting CD20, ADI-002 targeting glypican 3 protein (GPC3), and ADI-00x for solid tumors and hematological indications. These therapies aim to enable selective tumor targeting, facilitate immune responses, and improve patient persistence. The company generates revenue through the development and potential commercialization of its pipeline products, with ADI-001, ADI-002, and ADI-00x representing key therapeutic candidates for oncology markets. Adicet Bio, Inc. is a biotechnology firm targeting the oncology sector with its gamma delta T cell therapies, designed to address unmet medical needs in cancer treatment. The company's product portfolio consists of ADI-001, ADI-002, and ADI-00x, each targeting specific antigens for tumor targeting. ADI-001 focuses on CD20, ADI-002 on GPC3, and ADI-00x on solid tumors and hematological conditions. These therapies are developed for potential commercialization in the biopharmaceutical market, where pharmaceutical companies and healthcare providers may purchase or license the therapies for patient treatment. The company's revenue model relies on the progression of its pipeline products through clinical development and eventual market entry. ADI-001, ADI-002, and ADI-00x are the primary products driving potential revenue, with ADI-001 and ADI-002 currently in development for specific cancer indications. The firm's focus on allogeneic therapies positions it to serve patients requiring off-the-shelf treatments, differentiating from autologous approaches. Adicet Bio, Inc. aims to secure partnerships or direct sales for its therapies, targeting oncology specialists and hospitals as key buyers in the healthcare ecosystem. Adicet Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Adicet Bio stock

On Eulerpool you can find the complete historical development of Accounts Receivable Adicet Bio since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Adicet Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Adicet Bio

All Key Metrics — Adicet Bio